Definium Therapeutics, Inc. Segments Disclosure
The Company has one reportable segment relating to the research and development of the Company’s neurological drug development platform.
The Company’s CODM, its , reviews the Company’s operations, including reviewing budgets and trial related data, and decides how to allocate resources and assess performance. When evaluating the Company’s financial performance, the CODM regularly reviews total expenses and total assets and the CODM makes decisions using this information on a consolidated basis. The CODM uses consolidated net income or loss as a measure of profit or loss in allocating resources and assessing segment performance. In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense detail that is routinely reviewed by the CODM (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Research and development: |
|
|
|
|
|
|
||
Internal expenses |
|
$ |
32,834 |
|
|
$ |
23,513 |
|
External expenses |
|
|
84,831 |
|
|
|
41,784 |
|
Total |
|
|
117,665 |
|
|
|
65,297 |
|
General and administrative: |
|
|
|
|
|
|
||
Internal expenses |
|
|
22,612 |
|
|
|
18,986 |
|
External expenses |
|
|
26,032 |
|
|
|
19,633 |
|
Total |
|
|
48,644 |
|
|
|
38,619 |
|
Loss from operations |
|
|
(166,309 |
) |
|
|
(103,916 |
) |
Total other expense, net |
|
|
(17,484 |
) |
|
|
(4,763 |
) |
Net loss |
|
$ |
(183,793 |
) |
|
$ |
(108,679 |
) |
Internal expenses include employee-related costs such as salaries, related benefits, non-cash stock-based compensation expense for employees, and allocated operational expenses. External expenses include services rendered by third party providers for research and development as well as general and administrative activities.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.